2026 Primary hyperoxaluria type 3 indication strategy covering epidemiology, HOGA1 biology, active trials, transactions, unmet need, competition and market…
2026 Primary hyperoxaluria type 2 indication strategy covering epidemiology, GRHPR biology, active trials, transactions, unmet need, competition and market…